---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-25-000140"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2025-12-04T23:59:59+00:00"
generated_at: "2026-05-16T14:59:52.865284+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axogen receives FDA approval of BLA for Avance nerve allograft under Accelerated Approval pathway

## Summary
- FDA approved Biologics License Application for Avance (acellular nerve allograft) for sensory, mixed, motor nerve discontinuities in adults and pediatric patients 1 month+.
- Indications for sensory gaps >25mm and mixed/motor gaps approved under Accelerated Approval pathway; continued approval depends on confirmatory studies.
- Commercial launch of licensed Avance expected early Q2 2026; product remains available under current tissue framework until then.
- CEO Michael Dale says approval strengthens regulatory footing and confirms Avance as safe, pure, potent therapeutic option.

## SEC filing metadata
- accession: 0000805928-25-000140
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2025-12-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592825000140/0000805928-25-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592825000140/axgn-20251203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-25-000140
- JSON: https://secwatch.observer/filing/0000805928-25-000140.json
- Plain text: https://secwatch.observer/filing/0000805928-25-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.